Wealth Enhancement Advisory Services
HUMA icon

Wealth Enhancement Advisory Services’s Humacyte HUMA Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.7K Sell
50,030
-28,574
-36% -$26.5K ﹤0.01% 3970
2026
Q1 		$50.5K Buy
78,604
+68,464
+675% +$71.2K ﹤0.01% 3428
2025
Q4 		$11K Sell
10,140
-3,460
-25% -$4.9K ﹤0.01% 3630
2025
Q3 		$22.4K Sell
13,600
-7,986
-37% -$15.6K ﹤0.01% 3502
2025
Q2 		$49.2K Buy
+21,586
New +$41.5K ﹤0.01% 3228

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Wealth Enhancement Advisory Services's HUMA Position: Q2 2026 in Review

Wealth Enhancement Advisory Services reduced its Humacyte (HUMA) stake by 36% in Q2 2026, selling an estimated $26.5K and leaving 50,030 shares worth $34.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3970.

Wealth Enhancement Advisory Services first reported a position in HUMA in Q2 2025 and has held it in 5 quarters since. The position peaked at $50.5K in Q1 2026. 161 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Wealth Enhancement Advisory Services held 50,030 shares of Humacyte worth $34.7K as of Q2 2026.
  • Wealth Enhancement Advisory Services sold 28,574 Humacyte shares in Q2 2026, an estimated $26.5K.
  • Humacyte made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #3970 holding.
  • Wealth Enhancement Advisory Services first reported a position in Humacyte in Q2 2025 and has held it in 5 quarters since.
  • Wealth Enhancement Advisory Services's Humacyte position peaked at $50.5K in Q1 2026.
  • 161 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.